NZ764088A - Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan - Google Patents
Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphanInfo
- Publication number
- NZ764088A NZ764088A NZ764088A NZ76408815A NZ764088A NZ 764088 A NZ764088 A NZ 764088A NZ 764088 A NZ764088 A NZ 764088A NZ 76408815 A NZ76408815 A NZ 76408815A NZ 764088 A NZ764088 A NZ 764088A
- Authority
- NZ
- New Zealand
- Prior art keywords
- dextromethorphan
- bupropion
- compositions
- methods
- related compounds
- Prior art date
Links
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 title abstract 4
- 229960001985 dextromethorphan Drugs 0.000 title abstract 4
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title abstract 3
- 229960001058 bupropion Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002459 sustained effect Effects 0.000 title 1
- 206010057852 Nicotine dependence Diseases 0.000 abstract 1
- 208000025569 Tobacco Use disease Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the use of a combination of dextromethorphan and bupropion for treating nicotine addiction, by administration of 60-140 mg of dextromethorphan and 150-300 mg of bupropion (each in free base or salt form) for at least 8 consecutive days. The claimed treatment regime results in an AUC0-12 of dextromethorphan of 100-1686.3 ng•hr/mL on the eighth day of administration.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/550,618 US9198905B2 (en) | 2013-11-05 | 2014-11-21 | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US14/555,085 US9238032B2 (en) | 2013-11-05 | 2014-11-26 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
| US14/554,988 US9205083B2 (en) | 2013-11-05 | 2014-11-26 | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
| US14/554,947 US20150126542A1 (en) | 2013-11-05 | 2014-11-26 | Compositions and Methods for Increasing the Metabolic Lifetime of Dextromethorphan and Related Pharmacodynamic Effects |
| US14/602,177 US9402843B2 (en) | 2013-11-05 | 2015-01-21 | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
| US14/604,397 US9168234B2 (en) | 2013-11-05 | 2015-01-23 | Bupropion as a modulator of drug activity |
| US14/617,624 US9486450B2 (en) | 2013-11-05 | 2015-02-09 | Hydroxybupropion and related compounds as modulators of drug plasma levels |
| US14/628,062 US9402844B2 (en) | 2013-11-05 | 2015-02-20 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| NZ747111A NZ747111A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ764088A true NZ764088A (en) | 2023-02-24 |
Family
ID=84527790
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ764077A NZ764077A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
| NZ764088A NZ764088A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
| NZ764072A NZ764072A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ764077A NZ764077A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ764072A NZ764072A (en) | 2014-11-21 | 2015-05-01 | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Country Status (1)
| Country | Link |
|---|---|
| NZ (3) | NZ764077A (en) |
-
2015
- 2015-05-01 NZ NZ764077A patent/NZ764077A/en unknown
- 2015-05-01 NZ NZ764088A patent/NZ764088A/en unknown
- 2015-05-01 NZ NZ764072A patent/NZ764072A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ764077A (en) | 2022-12-23 |
| NZ764072A (en) | 2022-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001540A (en) | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity. | |
| MY192084A (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| UA122346C2 (en) | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | |
| SA518400356B1 (en) | Arginase inhibitors and their therapeutic applications | |
| SG10201810888XA (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| MY189466A (en) | Methods of modulating drug plasma levels using erythrohydroxybupropion | |
| EA201691454A1 (en) | COMPOSITIONS OF PRIDOPIDININE MODIFIED SHIPPING | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| MX2019003173A (en) | Combination therapy with controlled-release cnp agonists. | |
| MX2016009332A (en) | Ligand-cytotoxicity drug conjugate, preparation method therefor, and uses thereof. | |
| PH12020500076A1 (en) | Long-acting formulations | |
| MA39765A (en) | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use | |
| MY179783A (en) | Substituted bicyclic compounds | |
| ZA202200511B (en) | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis | |
| MX2018014129A (en) | Pharmaceutical composition comprising eteplirsen. | |
| MX2018011592A (en) | Compound having mutant idh inhibitory activity, preparation method and use thereof. | |
| PH12019500327A1 (en) | Indazole compounds for use in tendon and/or ligament injuries | |
| MX2016010892A (en) | Agent for improving or preventing progression of chronic kidney disease. | |
| MX2016014740A (en) | A method for treating movement disorders with befiradol. | |
| NZ764088A (en) | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan | |
| WO2015200768A3 (en) | Pharmacologic treatments of menière's disease | |
| MX2020001217A (en) | Methods of treating symptoms of gastroparesis using velusetrag. | |
| PH12016502547A1 (en) | Methods for treating infections | |
| MX2018001528A (en) | Pharmaceutical composition comprising sumatripan for treating migraine. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| S38C | Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended | ||
| S38C | Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended |